Allied Health & Imaging · Independent exam preparation
Certified Clinical Transplant Coordinator (CCTC) Examination Study Guide
A selective study guide aligned with the ABTC CCTC detailed content outline effective July 1, 2026. The official outline defines the full examination scope, including organ-specific, multi-organ, and adult and pediatric topics. This guide teaches selected practical concepts across all three domains; it is not an exhaustive account of every task, organ-specific topic, or protocol.
By CertMedbry · Updated 13 October 2026
The American Board for Transplant Certification (ABTC) awards the Certified Clinical Transplant Coordinator (CCTC) credential. The current outline covers kidney, pancreas, liver, lung, intestine, heart, multiple-organ transplantation, and basic adult and pediatric principles. These questions and flashcards are independently authored learning materials, not official or recalled ABTC items. Clinical examples teach coordination and reasoning, not individualized medical advice. Follow current transplant-team protocols and applicable policy.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
How many items are on the CCTC examination, and how many are scored?
The current ABTC handbook reports 175 items: 150 scored and 25 unscored pretest items. ABTC publishes 46, 46, and 58 scored items across the three domains.
ABTC Candidate Handbook — currently linked August 13, 2026 file
How long is the CCTC examination?
The current handbook specifies three hours of testing time.
ABTC Candidate Handbook — currently linked August 13, 2026 file
Which outline and domain weights does this guide use?
The guide uses the CCTC outline effective July 1, 2026. ABTC publishes Transplant Education at 31%, Pre-Transplant Evaluation and Management at 30%, and Post-operative Monitoring, Evaluation, and Reporting at 39%. The official outline is the full examination scope; this guide is selective.
ABTC Candidate Handbook — currently linked August 13, 2026 file
Does the older two-domain outline still apply?
No. The March 2026 handbook's two-domain outline was effective only through June 30, 2026. The current outline is the three-domain version effective July 1, 2026.
ABTC Candidate Handbook — March 12, 2026 file · ABTC Candidate Handbook — currently linked August 13, 2026 file
How are these practice questions distributed by domain?
These are learning questions, not a weighted mock examination. The 20 questions include 4 Transplant Education, 8 Pre-Transplant Evaluation and Management, and 8 Post-operative Monitoring, Evaluation, and Reporting items. The official domain weights are 31%, 30%, and 39%, respectively.
ABTC Candidate Handbook — currently linked August 13, 2026 file
What organs and populations are within CCTC scope?
ABTC includes kidney, pancreas, liver, lung, intestine, heart, multiple-organ transplantation, and basic adult and pediatric principles. The outline also includes U.S. OPTN/UNET tasks. This guide is selective rather than comprehensive; use current policy and the relevant transplant program's protocols.
ABTC Candidate Handbook — currently linked August 13, 2026 file · OPTN Policies — effective October 1, 2026
The official examination name is Certified Clinical Transplant Coordinator (CCTC). The shortened workbook label Certified Transplant Coordinator maps to this examination; the supplied sources do not establish a separate current examination with that shorter name. CCTC is distinct from CCTN, CPTC, CTP, and CTFC. This guide uses the three-domain outline effective July 1, 2026, not the historical two-domain outline effective through June 30, 2026. OPTN and UNET references are U.S.-specific.
Outline used: ABTC CCTC detailed content outline effective July 1, 2026, read in the currently linked Candidate Handbook, whose filename identifies August 13, 2026. Verified on October 13, 2026, Asia/Hong_Kong. The workbook label 'Certified Transplant Coordinator (CCTC)' omits 'Clinical' from ABTC's official examination name; it maps to this CCTC examination, with the assigned slug preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Transplant Education31%
1.How should transplant education frame benefits, risks, and alternatives?
Support informed choice rather than persuasion. Explain potential benefits alongside material risks, including infection, graft failure, and death, and discuss relevant alternatives in the person's clinical context. Transplantation does not guarantee a cure or a particular outcome. The clinical team determines suitability; education helps the person compare options with their goals and understand ongoing treatment and monitoring needs.
Apply it
If a candidate believes transplant guarantees a cure, clarify that outcomes are not guaranteed. Ask which outcomes matter to the candidate and arrange discussion of alternatives the team considers clinically relevant. Invite questions and allow time to consider tradeoffs without pressure.
Common pitfall: Do not present transplantation as risk-free or imply an alternative is suitable without team assessment. Avoid steering a person toward a decision before exploring their values and questions. Balanced education supports choice; it does not replace the clinical team's individualized recommendation.
ABTC Candidate Handbook — currently linked August 13, 2026 file
2.How can teach-back show whether education worked?
Ask the learner to explain an important point in their own words or demonstrate a skill. Teach-back assesses the clarity of the explanation, not the learner's intelligence or compliance. Use plain language, focus on important actions, and reteach differently if a gap appears. Adapt communication to language, culture, cognition, age, and other learning needs, then check understanding again.
Apply it
After explaining fever-reporting instructions, ask the recipient what they would do if fever developed at home. If the answer is unclear, explain the point another way and check again. Keep the exchange respectful and focused on whether the instruction was clear and actionable.
Common pitfall: A yes-or-no question does not demonstrate comprehension. Do not use teach-back to shame or blame the learner; treat an incorrect response as a cue to improve the explanation. Avoid rote repetition without checking whether the person can apply the instruction in a realistic situation.
AHRQ: Use the Teach-Back Method, Tool 5 · ABTC Candidate Handbook — currently linked August 13, 2026 file
3.How should transplant and living-donor indications and contraindications be discussed?
Explain that indications and contraindications depend on organ, clinical condition, expected benefit, and applicable criteria. A diagnosis alone does not establish eligibility. A relative contraindication may warrant mitigation or individualized balancing; an absolute contraindication under applicable criteria precludes proceeding at that time. Suitability is an individualized clinical and program decision, not something established by education alone.
Apply it
If a candidate asks whether one diagnosis automatically rules out transplant, explain that the team considers the full clinical picture and applicable organ-specific criteria. Identify questions for team review rather than promising acceptance or exclusion.
Common pitfall: Do not promise acceptance, label every abnormality an absolute contraindication, or assume the same criteria apply to every organ or program. Separate general education from the team's individualized determination. Do not diagnose or decide eligibility independently.
ABTC Candidate Handbook — currently linked August 13, 2026 file · HRSA OPTN: Living Donation FAQs
4.How should living-donor education protect voluntariness?
Living-donor education should support a voluntary, informed decision and cover evaluation, risks, alternatives, and follow-up. Independent donor advocacy offers a confidential route to discuss concerns and supports the donor's interests. A donor should be able to withdraw without pressure to disclose a private reason to the recipient. Include support people when appropriate and with the donor's agreement, while protecting privacy and autonomy.
Apply it
If a donor candidate privately reports family pressure, arrange a confidential discussion with the independent donor advocate and follow the center's process for protecting the donor's choice. Limit disclosure of the private conversation and clarify how necessary communication will be handled.
Common pitfall: Family enthusiasm does not establish free consent. Do not disclose private donor information to the recipient without authorization or use a joint meeting to pressure the donor. Do not frame withdrawal as failure or ask the donor to justify a private decision to the recipient.
HRSA OPTN: Living Donation FAQs · ABTC Candidate Handbook — currently linked August 13, 2026 file
5.What should living kidney or liver donors learn about procedures and recovery?
Explain the general surgical pathway, expected perioperative care, and recovery issues in language suited to the person. The CCTC outline includes immediate postoperative care, pain management, bleeding and infection risks, postoperative testing, and possible delay in return to work. The operating team provides procedure-specific details, restrictions, and individual recovery expectations. Explain whom to contact after discharge and distinguish donor follow-up from recipient care.
Apply it
If a donor expects to return immediately to heavy work, review the surgical team's activity restrictions and recovery plan, then ask the donor to explain it in their own words. Refer procedure-specific questions and recovery estimates to the donor's clinical team.
Common pitfall: Do not promise a generic recovery timeline or substitute general education for the surgeon's procedure-specific consent discussion. Clarify uncertainty rather than offering an unsupported estimate. Avoid implying recovery will be identical for kidney and liver donors or across individuals.
ABTC Candidate Handbook — currently linked August 13, 2026 file · HRSA OPTN: Living Donation FAQs
6.Which short- and long-term donor complications should be discussed?
Donor education should cover possible complications without implying donation is risk-free. The CCTC outline includes infection, persistent pain, wound concerns, delayed return to work, hernia, changes in organ function, and possible psychological effects. Explain center-specific warning signs, contact pathways, activity instructions, and scheduled reassessment. The donor's own health remains important regardless of the recipient's outcome.
Apply it
If a donor reports difficulty returning to work, review the recovery plan and coordinate questions with the clinical team responsible for donor follow-up. Ask whether pain, mood, or another concern is affecting recovery and route it through the appropriate clinical pathway.
Common pitfall: Do not promise donation has no lasting effects or assume the donor is well because the recipient is doing well. Avoid treating possible complications as certain outcomes for every donor. Do not dismiss a concern because it is not listed as common in general education.
ABTC Candidate Handbook — currently linked August 13, 2026 file · HRSA OPTN: Living Donation FAQs
7.Why should living-donor follow-up continue after surgery?
Follow-up supports assessment of medical and psychosocial concerns after donation. Donors should know which visits or tests are expected and how to contact the center. If travel, finances, or another barrier interferes, help coordinate an appropriate plan. Donor follow-up is independent of the recipient's clinical course and should not be considered complete merely because surgery was uncomplicated.
Apply it
If a donor misses follow-up because travel is difficult, explore the barrier and coordinate with the center rather than assuming assessment is no longer needed. Confirm the next agreed step and who is responsible for arranging it.
Common pitfall: Recipient outcomes do not substitute for independent donor assessment. Use the donor's program-specific plan and current requirements rather than promising a universal schedule. Do not close follow-up solely because the donor reports feeling well.
HRSA OPTN: Living Donation FAQs · ABTC Candidate Handbook — currently linked August 13, 2026 file
8.What medication information should recipients understand before transplant?
Recipients should understand the purpose of their prescribed regimen, how to follow its specific instructions, important adverse effects and interactions, and whom to contact before a medication change. Many transplant medicines require ongoing monitoring. Teach a practical routine and the center's plan for missed doses or access problems. Feeling well is not a reason to stop or adjust prescribed treatment independently.
Apply it
If a candidate asks whether they can stop a medicine after transplant when they feel well, explain that changes require team direction and use teach-back. Ask what might make it difficult to obtain or take medicines as prescribed, then connect the person with appropriate support.
Common pitfall: Do not treat medicines as interchangeable or give unsupervised dose advice. Verify the current regimen and refer individualized questions to the responsible clinician or pharmacist. Do not promise side effects will not occur or that medicine can be stopped without a team decision.
DailyMed: Tacrolimus Capsules Prescribing Information · ABTC Candidate Handbook — currently linked August 13, 2026 file
9.How should recipients be taught to recognize and report possible rejection?
Rejection can be acute or chronic, and symptoms alone cannot confirm or exclude it. Teach recipients the symptoms and changes their center wants reported, and reinforce diagnostic surveillance. Prompt reporting supports assessment; diagnosis and treatment require clinical evaluation. Recipients should attend monitoring even when they feel well and follow their program's contact instructions.
Apply it
If a recipient reports new pain near the graft despite normal home measurements, reinforce prompt contact with the transplant center and document the communication and disposition. Ask about timing and associated symptoms, then follow the center's triage process.
Common pitfall: Absence of classic symptoms does not rule out rejection, and one nonspecific symptom does not prove it. Do not tell a recipient to change immunosuppression based on symptoms alone. Normal home readings do not rule out a graft problem.
ABTC Candidate Handbook — currently linked August 13, 2026 file · NIDDK: Kidney Transplant
10.How should recipients be taught to report possible infection?
Recipients should know the center's instructions for reporting possible infection, including symptoms such as fever, productive cough, nausea, or purulent drainage listed in the CCTC outline. Immunosuppression can make infection consequential, but symptoms do not establish a diagnosis. Explain whom to contact and how urgently, including what to do outside regular clinic hours.
Apply it
If a recipient reports a new productive cough, use the center's reporting pathway and ask about timing and associated symptoms. Provide the appropriate contact route and confirm the recipient knows whether urgent evaluation is needed.
Common pitfall: Do not reassure solely because symptoms seem mild or recommend leftover treatment. Use the recipient's actual instructions and team assessment, and escalate according to urgency. Do not advise stopping immunosuppressive medicines without direction.
ABTC Candidate Handbook — currently linked August 13, 2026 file
11.Which food-safety messages matter for an immunocompromised recipient?
Immunosuppression can make foodborne illness more consequential. CDC guidance covers safer food choices and careful handling, including avoiding raw or undercooked higher-risk foods and preventing contamination during preparation. Discuss safe cooking, storage, and clean preparation surfaces. Reinforce handwashing and avoiding cross-contamination between raw foods and ready-to-eat foods.
Apply it
If a recipient asks about raw seafood at a celebration, explain that raw or undercooked seafood is a higher-risk choice for people with weakened immune systems and discuss safely cooked options. Ask which food situations are most relevant so advice is practical.
Common pitfall: A restaurant setting does not remove risk from inadequate cooking or cross-contamination. Do not imply every food has identical risk or provide advice that conflicts with current guidance. Avoid vague instructions that leave the recipient unsure how to prepare or store food safely.
CDC: Safer Food Choices for People With Weakened Immune Systems · ABTC Candidate Handbook — currently linked August 13, 2026 file
12.Why do vaccine decisions require transplant-team review?
Vaccine safety and usefulness depend on immune status, vaccine type, and transplant timing. CDC guidance distinguishes live vaccines, which require particular caution in altered immunocompetence, from non-live vaccines. Identify the vaccine and timing, then coordinate individualized guidance with the transplant team and relevant clinicians.
Apply it
If a recipient asks about a live vaccine before planned immunosuppression, identify the vaccine and timing and request transplant-team guidance before routine administration. Document the question and communicate the recommendation through the appropriate care pathway.
Common pitfall: Do not conclude that every vaccine is contraindicated after transplantation or treat live vaccination as routine without review. Avoid a universal schedule where individual timing matters. Seek prompt advice if a vaccine has already been administered or exposure has occurred.
CDC: Altered Immunocompetence · ABTC Candidate Handbook — currently linked August 13, 2026 file
13.How can home monitoring support care without replacing the recipient's surveillance plan?
Home measurements such as temperature, blood pressure, and weight can help recipients notice changes and share useful information with the team. They are observations, not a substitute for organ-specific testing or clinical assessment. Teach the recipient which measurements the program requests, how to report concerns, and how to keep scheduled laboratory and clinic appointments even when they feel well.
Apply it
If a recipient reports stable home measurements but has missed scheduled follow-up, explain that home monitoring does not replace the program's testing and visits. Ask what is preventing attendance and help arrange the next step.
Common pitfall: Do not create thresholds absent from the recipient's instructions or independently alter the monitoring schedule. Reassuring home readings do not rule out a graft problem or replace ordered tests. Follow the actual organ-specific plan.
ABTC Candidate Handbook — currently linked August 13, 2026 file · NIDDK: Kidney Transplant
14.How can educators elicit patient goals without implying an alternative is suitable?
Ask what outcomes matter to the candidate, what burdens concern them, and what they understand about available options. Reflect those priorities in a conversation with the clinical team. Discussing dialysis, medical therapy, mechanical support, or palliative care does not establish that an option fits this person; suitability and sequencing require clinical assessment.
Apply it
If a candidate values time at home and asks whether an alternative may better fit that goal, explore what matters and arrange an individualized team discussion. Summarize the candidate's priorities accurately so the team can address them.
Common pitfall: Do not infer goals from age, disability, or family views, and do not promise that an alternative is clinically available or preferable. Ensure the candidate's own values are heard. Do not present one option as inevitable before suitability and preferences are discussed.
ABTC Candidate Handbook — currently linked August 13, 2026 file
15.How should education adapt to different learners and support people?
ABTC identifies age, culture, and cognitive ability as factors in learning needs. Use accessible language and appropriate interpretation or communication supports, invite the learner's priorities, and check understanding with teach-back or demonstration. Include support people when the patient or donor agrees and when appropriate, while protecting privacy and autonomy.
Apply it
For a pediatric candidate and caregiver receiving complex instructions, use age-appropriate explanations, follow consent and privacy processes, and check each person's understanding and role. Arrange an interpreter or other communication support when needed rather than relying on a family member by default.
Common pitfall: Do not infer poor understanding from accent, disability, or culture. A support person is not automatically authorized to receive confidential information or make decisions for the patient. Written material alone may not meet a learner's communication needs.
AHRQ: Use the Teach-Back Method, Tool 5 · ABTC Candidate Handbook — currently linked August 13, 2026 file
16.Why do donor and recipient confidentiality matter?
Donor and recipient evaluations contain sensitive information. Confidentiality protects trust and supports voluntary decision-making, especially when a donor has concerns or chooses not to proceed. Share information only through authorized channels and follow applicable policy and law. Communicate necessary clinical information to authorized team members so confidentiality does not interfere with safe care.
Apply it
If a recipient asks why a potential donor's evaluation stopped, explain that donor details are confidential and direct the question through the center's approved process. Avoid confirming private clinical details, and ensure necessary team communication follows authorization and policy.
Common pitfall: Do not disclose private donor medical or psychosocial findings to reassure a recipient. Confidentiality does not justify withholding information from authorized clinicians who need it for care. Avoid promises of secrecy that conflict with applicable policy or clinical communication.
HRSA OPTN: Living Donation FAQs · OPTN Policies — effective October 1, 2026
17.How should the transplant team's shared roles be explained?
Transplant care involves professionals with different responsibilities, including physicians, coordinators, pharmacy, social work, nutrition, finance, and psychosocial services. Explain whom to contact and how information moves between providers. Refer concerns outside the coordinator's scope, and use a clear handoff with follow-through so the recipient knows what will happen next.
Apply it
If a recipient reports medication-cost concerns and uncertainty about diet advice, connect them with financial and nutrition services and ensure the transplant team receives both concerns. Confirm who will follow up and whether the recipient has a practical way to contact each service.
Common pitfall: Do not try to resolve every specialty issue alone or assume another service already knows. A referral needs a clear handoff, responsible contact, and follow-through. Do not give conflicting advice outside your role or leave the recipient unsure who owns the next step.
AHRQ: Help Patients Pay Less for Medicine, Tool 19 · ABTC Candidate Handbook — currently linked August 13, 2026 file
Pre-Transplant Evaluation and Management30%
18.When a potential deceased-donor offer is being considered, what should the coordinator support?
Review and present donor information alongside the candidate's current condition to the transplant physician or team. Help identify matching and suitability factors such as ABO compatibility, organ size, and applicable antibody or crossmatch findings; route concerning or incomplete information promptly. Document offer acceptance according to program process. Acceptance is not informed surgical consent, and the coordinator does not independently determine medical suitability.
Apply it
For an offer with a potentially concerning compatibility result, communicate it to the transplant physician and histocompatibility team, follow the center's testing process, and document the outcome. Coordinate consent and logistics only as the clinical decision and workflow permit.
Common pitfall: Do not treat offer review, preliminary compatibility, or candidate acceptance as a substitute for clinical suitability review or required surgical consent. Follow current OPTN policy and center procedures. Do not present an incomplete test result as a definitive compatibility decision.
ABTC Candidate Handbook — currently linked August 13, 2026 file · OPTN Policies — effective October 1, 2026
19.How should cardiac evaluation findings be advanced to a team decision?
Confirm cardiac studies and specialist reports are available, current, and interpreted by the responsible clinician. A completed study is not equivalent to cardiac clearance. Track unresolved questions, such as whether additional testing or consultation is needed, and make them visible to the team. The team's organ-specific assessment determines how findings affect suitability; a single result does not decide candidacy.
Apply it
If a candidate has an abnormal cardiac study and a cardiology report is pending, confirm its status and route the finding for review. Present the unresolved question at team review and track requested testing or recommendations to completion.
Common pitfall: Do not label a candidate cleared because a test was performed, or diagnose risk from an isolated result. Distinguish test completion from interpretation and recommendation. Do not omit the pending interpretation from the candidate's status or evaluation summary.
ABTC Candidate Handbook — currently linked August 13, 2026 file
20.How should objective candidate data and comorbidities guide additional consultation?
Review laboratory results, diagnostic findings, and medical and surgical history to identify questions requiring clarification. Potential consultations include cardiology, pulmonology, infectious disease, oncology, nutrition, pharmacy, or psychosocial services. The coordinator organizes information and recognizes when review is needed; specialists and the team interpret clinical significance. Missing information is not a normal result, and an abnormal value needs context.
Apply it
If a candidate has recurrent infection history and incomplete infectious-disease review, confirm source records are available, coordinate indicated consultation, and track recommended testing. Present the question and its status accurately to the team.
Common pitfall: Do not turn a screening result into a diagnosis or decide candidacy independently. Verify results and context before presenting them as established facts. A referral placed or appointment scheduled is not completed clinical interpretation.
ABTC Candidate Handbook — currently linked August 13, 2026 file
21.What makes a useful multidisciplinary evaluation summary?
Bring together relevant results, consultations, comorbidities, barriers, and unanswered questions in a form the team can act on. Separate documented facts from interpretation, identify pending tests, and note applicable policy requirements. The summary supports a team recommendation; it is not a unilateral approval or exclusion decision. Include dates and sources so team members can verify information.
Apply it
Before a selection meeting, identify a completed cardiac review, pending infection assessment, and transportation barrier, clearly labeling each status and its source. Note actions already taken and the question the team needs to resolve.
Common pitfall: Do not present a scheduled consultation as complete or omit a safety-relevant finding. State uncertainty explicitly and identify information still needing review. Avoid framing unresolved issues as settled conclusions or leaving follow-up responsibility unclear.
ABTC Candidate Handbook — currently linked August 13, 2026 file
22.How should transplant and living-donor suitability be determined?
Suitability is determined from the whole evaluation and applicable organ-specific criteria, not a single historical behavior or isolated risk factor. KDIGO kidney-candidate guidance recommends considering candidates with a history of nonadherence unless ongoing, health-compromising nonadherent behavior is present. Separately, barriers to adherence should be assessed and addressed as part of candidate evaluation; prior education, counseling, or support are not prerequisites stated in that recommendation.
Apply it
If a kidney candidate has missed medication or clinic appointments, clarify the pattern and current impact, assess barriers such as access or understanding, and coordinate appropriate education or support. Present whether the behavior is historical or ongoing and health-compromising for team review.
Common pitfall: Do not equate one missed visit or a past history with ongoing, health-compromising behavior. Do not add a requirement that education, counseling, or support must first fail before applying KDIGO's distinction. Avoid applying kidney-candidate guidance universally or declaring suitability from incomplete information.
KDIGO 2020 Clinical Practice Guideline on Kidney Transplant Candidate Evaluation · ABTC Candidate Handbook — currently linked August 13, 2026 file
23.How should adherence barriers be assessed during candidacy review?
A missed visit or difficulty following a plan warrants inquiry into the cause rather than assumptions about willingness. Barriers can include health literacy, mental health, transportation, finances, caregiver support, or medication access. Coordinate education or referrals and communicate unresolved issues to the team. Consider whether proposed support is accessible and acceptable to the candidate.
Apply it
If a candidate missed appointments because transportation repeatedly failed, clarify the pattern, connect the candidate with available support, and report both the barrier and response. Agree on a practical next step and follow up on whether it resolved the access problem.
Common pitfall: Do not equate structural access problems with deliberate refusal. Do not omit a persistent unresolved concern from individualized team assessment or promise support will change the decision. Use specific, nonstigmatizing language in documentation.
KDIGO 2020 Clinical Practice Guideline on Kidney Transplant Candidate Evaluation · ABTC Candidate Handbook — currently linked August 13, 2026 file
24.What does cPRA communicate about HLA sensitization?
Calculated panel reactive antibody estimates the proportion of donors in a reference population expected to be incompatible because of unacceptable HLA antigens. It is a population-level sensitization measure, not a direct prediction that a particular offer will be accepted or when transplant will occur. Interpret it alongside antibody specificity, donor HLA, and laboratory assessment.
Apply it
If a candidate asks whether high cPRA proves a particular donor is incompatible, explain that donor-specific assessment is needed and cPRA alone does not answer the offer-level question. Route antibody or crossmatch questions to the histocompatibility laboratory and transplant team.
Common pitfall: Do not confuse cPRA with a rejection diagnosis, graft-function measure, or donor-specific crossmatch result. Avoid an offer decision based on cPRA alone or a promise about exact waiting time.
HRSA OPTN: CPRA Calculator · OPTN 2025 Histocompatibility Laboratory Guidance Document
25.Why do virtual and physical crossmatches require careful interpretation?
Virtual assessment and physical laboratory testing are different methods of evaluating compatibility. Interpretation depends on recipient antibody data, donor HLA information, laboratory methods, and program protocol. Ensure results reach the responsible team and histocompatibility laboratory. Confirm which method is required for the specific offer and whether the necessary information is current.
Apply it
If an offer has a preliminary virtual assessment while a required final result is pending, confirm laboratory and protocol status before describing compatibility as established. Communicate the pending result and next step to the team and document final review when available.
Common pitfall: Do not treat a virtual crossmatch as an automatic substitute for every physical test or interpret antibody results without donor-specific context and laboratory input. Do not let a preliminary result become an unsupported offer decision.
OPTN 2025 Histocompatibility Laboratory Guidance Document · ABTC Candidate Handbook — currently linked August 13, 2026 file
26.Why must waitlist documentation and data be accurate?
OPTN/UNET information supports listing, status, allocation, and required reporting. Verify entries against source documentation and applicable policy, resolve discrepancies with the responsible team, and retain appropriate documentation. Validate key candidate information before entering or updating data. Accurate data support allocation integrity and reliable candidate communication.
Apply it
If listed height conflicts with a current measurement, check the source record, resolve the difference, and update through the approved process. Record the basis for correction and confirm the updated information is reflected where required.
Common pitfall: Do not copy forward values without confirming validity or select a value to produce a desired priority. Use documented sources and current policy. Do not submit uncertain estimates as facts or assume an electronic entry is corrected without verification.
OPTN Policies — effective October 1, 2026 · ABTC Candidate Handbook — currently linked August 13, 2026 file
27.How does MELD support liver allocation decisions?
OPTN uses MELD for candidates age 12 and older and PELD for candidates younger than 12. The sex input applies only to the adult MELD calculation for candidates age 18 or older. MELD supports assessment of medical urgency but does not guarantee an offer or transplant date; it is not the only factor relevant to every allocation decision. Verify values and documentation with the responsible team.
Apply it
If a candidate's laboratory information changed but allocation data are outdated, verify source values and follow current OPTN procedures with the responsible team. Confirm the update is completed and communicate status using the team's reviewed information.
Common pitfall: Do not promise a wait time from a score or treat MELD as a complete measure of every clinical need. Do not calculate from unverified values, use adult MELD in place of applicable pediatric PELD, or rely on outdated policy.
HRSA OPTN: Questions and Answers About Liver Allocation · HRSA OPTN: MELD Calculator · OPTN Policies — effective October 1, 2026
28.What pulmonary information may need review during lung-transplant candidate evaluation?
Coordinate review of pulmonary history, objective studies, and relevant consultations. Identify missing reports, changes in clinical condition, and questions requiring specialist interpretation. A completed pulmonary-function study is not equivalent to an interpreted assessment of disease and risk. The team determines suitability and whether further evaluation is needed; the coordinator assembles accurate information, closes gaps, and communicates next steps.
Apply it
If a lung candidate has a new pulmonary study but no specialist interpretation, confirm the report is available, route it to the responsible team, and track requested testing or consultation. Label the study complete but interpretation pending in the summary.
Common pitfall: Do not equate a completed pulmonary test with clearance or assume one abnormal finding alone determines candidacy. Use the team's criteria and review process. Do not describe an unresolved result as normal or final.
ABTC Candidate Handbook — currently linked August 13, 2026 file
29.What tumor and AFP criteria must be checked when evaluating standardized HCC MELD exception eligibility?
For the standardized HCC pathway, qualifying T2 tumor burden must consist of OPTN Class 5 lesions: one lesion measuring 2–5 cm, or two to three lesions each measuring 1–3 cm. The candidate must also meet the applicable policy conditions, including absence of macrovascular invasion and extrahepatic spread. If AFP was above 1,000 ng/mL, it must fall below 500 ng/mL after locoregional therapy and remain below 500 for standardized eligibility. AFP at or above 500 ng/mL after therapy at any time requires referral for National Liver Review Board (NLRB) consideration. Verify current OPTN policy.
Apply it
When reviewing a candidate’s HCC exception documentation, confirm that the imaging identifies each lesion as OPTN Class 5 and records lesion number and measurements. Also check for documented macrovascular invasion or extrahepatic spread, and review AFP values in sequence alongside locoregional treatment dates. If AFP was initially above 1,000 ng/mL, a single post-treatment value below 500 is not enough if a later value reaches or exceeds 500; flag that result for NLRB referral. Coordinate submission and follow-up through the transplant program’s authorized OPTN process, using current policy.
Common pitfall: Do not treat lesion size alone as sufficient: the qualifying T2 lesions must be OPTN Class 5, and the other applicable tumor criteria must also be met. Do not interpret an AFP decline below 500 as permanently satisfying the standardized pathway if the value later rises to 500 or higher after locoregional therapy; that situation requires NLRB consideration. A submitted request does not itself establish eligibility or priority, and a nonstandard review is not guaranteed approval. Confirm current OPTN policy before advising candidates about status or priority.
OPTN Policies — effective October 1, 2026 · HRSA OPTN: Questions and Answers About Liver Allocation
30.How should possible infection or colonization affect kidney-candidate evaluation?
Distinguish active infection from asymptomatic colonization and obtain clinical interpretation of the organism, site, and candidate's condition. KDIGO kidney-candidate guidance states that asymptomatic bacterial, parasitic, or fungal colonization alone should not exclude a candidate; drug-resistant organism colonization should be managed under local protocols. Communicate results and facilitate the team-directed plan rather than diagnosing or prescribing treatment.
Apply it
If screening identifies asymptomatic colonization, relay the result and context to the team, confirm protocol review, and document the decision and follow-up. If symptoms or findings raise concern for active infection, communicate them promptly for separate clinical assessment.
Common pitfall: Do not label colonization as active infection or automatically exclude a candidate. Do not initiate treatment independently; follow clinical review and local protocols. Do not dismiss a finding without confirming team review.
KDIGO 2020 Clinical Practice Guideline on Kidney Transplant Candidate Evaluation · ABTC Candidate Handbook — currently linked August 13, 2026 file
31.What should be coordinated when evaluating a kidney-pancreas candidate?
A kidney-pancreas evaluation involves information relevant to both grafts, the candidate's current condition, and applicable matching and allocation processes. The pancreas contributes endocrine function, including regulation of blood glucose; kidney and pancreas considerations therefore require review of their respective clinical information. Present findings for each organ to the multidisciplinary team and coordinate consultations, testing, compatibility review, and logistics. Suitability for one organ does not establish suitability for the other.
Apply it
If a kidney-pancreas candidate has a potential offer, confirm current candidate information and donor and compatibility details for both organs reach the responsible team. If there is a concern about kidney function or glucose regulation, identify which graft-specific information is available and coordinate review of both as relevant. Document the team's decision and next steps.
Common pitfall: Do not assume an offer or finding relevant to one graft automatically resolves review of the second graft. Stable kidney findings do not by themselves establish normal pancreas function, and vice versa. Follow multi-organ allocation policy and center procedures.
HRSA OPTN: Pancreas · OPTN Policies — effective October 1, 2026 · ABTC Candidate Handbook — currently linked August 13, 2026 file
32.What does inactive status mean for a transplant candidate, and how should a change be managed?
Inactive status is different from removal: the candidate remains registered on the waiting list but is not eligible to receive deceased-donor organ offers while inactive. For example, a newly diagnosed active bloodstream infection may prompt the transplant team to reassess readiness and decide whether the candidate should be temporarily inactive. The clinical decision belongs to the transplant program’s responsible team; designated program personnel with appropriate system access make the authorized UNet status update. The candidate must be informed of the status and its practical effect, and the program should document the reason and follow-up plan.
Apply it
If a listed candidate reports a new infection, promptly relay the information to the responsible transplant team. If the team determines that the candidate is temporarily not eligible for offers, ensure authorized personnel update the listing to inactive, document the decision, rationale, effective date, and reassessment plan, and explain to the candidate that offers will not be received while inactive. When readiness is reassessed, the team must determine whether reactivation is appropriate and ensure the authorized update is made.
Common pitfall: Do not equate inactive status with removal from the list, or assume that a clinical change automatically changes listing status. Conversely, do not leave a candidate active when the team has determined that the candidate is not currently eligible for offers. Coordinators should not independently make the clinical readiness decision or promise reactivation; confirm that the decision, system update, and candidate communication are completed and documented under current OPTN policy.
OPTN Policies — effective October 1, 2026 · ABTC Candidate Handbook — currently linked August 13, 2026 file
33.What must preoperative coordination establish before a transplant proceeds?
Coordinate required compatibility testing, tissue typing, consent, admissions, laboratory or blood-bank needs, and facility logistics. Verify completion and review status of procedures and results, and communicate timing and expectations to the candidate or donor. The responsible team interprets abnormal findings and confirms readiness. Logistical readiness does not substitute for informed consent or clinical clearance.
Apply it
If admission is planned but a required compatibility result is unconfirmed, contact the laboratory and clinical team, resolve the gap, and communicate any timing change. Confirm the candidate has an opportunity to raise questions before proceeding.
Common pitfall: A scheduled test is not a completed, reviewed result. A signed form does not resolve unanswered consent questions or establish clinical readiness. Do not assume an anticipated result will be normal or that all departments have completed their steps.
ABTC Candidate Handbook — currently linked August 13, 2026 file · OPTN 2025 Histocompatibility Laboratory Guidance Document
34.How can psychosocial and financial barriers be incorporated fairly?
Evaluation may identify barriers involving medication affordability, transportation, support, or mental health. Coordinate referrals and practical assistance, and report what remains unresolved. A barrier is information for multidisciplinary assessment, not a judgment about worthiness. Decisions remain individualized and subject to program criteria and applicable policy. Record what support was offered and whether the candidate could access it.
Apply it
If a candidate says insurance approval may lapse before evaluation is complete, refer the issue to financial coordination and communicate the timing concern to the team. Confirm who will follow up and whether documentation is needed.
Common pitfall: Do not conceal an unresolved access issue or promise coverage or listing approval that has not been confirmed. Report barriers respectfully and accurately, including whether proposed help is available. Do not equate financial or social barriers with lack of interest in transplant.
AHRQ: Help Patients Pay Less for Medicine, Tool 19 · ABTC Candidate Handbook — currently linked August 13, 2026 file
35.Why must pediatric and adult transplant pathways not be treated as interchangeable?
Age can affect evaluation, communication, support needs, consent processes, and organ-size considerations. Coordinate with the appropriate pediatric or adult team and follow relevant program and jurisdictional requirements, including consent or assent processes where applicable. For a pediatric offer, size and the child's clinical context require appropriate team review. General coordination principles may transfer, but evaluation and legal requirements need context-specific review.
Apply it
If a pediatric candidate has a potential donor offer with a size question, ensure the pediatric team reviews relevant measurements and communicates its decision through the appropriate family process. Track any additional testing or consent steps requested by that team.
Common pitfall: Do not copy an adult consent assumption or pathway into pediatric care. Age alone does not determine suitability or offer acceptance. Avoid assuming a caregiver is authorized to receive every detail or make every decision.
ABTC Candidate Handbook — currently linked August 13, 2026 file · OPTN Policies — effective October 1, 2026
36.What evaluation needs should be considered for a candidate for intestinal transplantation?
Short gut syndrome is a common reason for intestinal transplantation consideration, but individual suitability depends on full clinical evaluation. Transplant options may include small-bowel transplantation alone, liver-small-bowel transplantation, or multivisceral transplant. Because the intestine supports absorption of nutrients and fluid, coordinate review of intestinal function, the candidate's condition, and multidisciplinary findings; ensure each proposed graft is assessed. The transplant team determines suitability and further assessment.
Apply it
If a candidate with short gut syndrome is being considered for a combined transplant, track intestinal and other organ-specific consultations and ensure the evaluation summary identifies what remains pending. Confirm relevant specialists have the necessary information and route new concerns about intestinal function to the team for review.
Common pitfall: Do not assume short gut syndrome alone establishes candidacy or determines transplant type. Do not treat intestinal evaluation as interchangeable with kidney surveillance or another organ's pathway. Avoid independently deciding suitability; follow the program's organ-specific assessment process.
HRSA OPTN: Intestine · ABTC Candidate Handbook — currently linked August 13, 2026 file
37.How should candidates be informed about waitlist communication and contact changes?
Maintain current contact information and follow applicable notification requirements. Explain how candidates can report illness, infection, insurance, or travel changes that could affect readiness. Document important exchanges and verify time-sensitive contact instructions are usable. This communication task is distinct from changing listing status: follow status decisions and updates through the authorized process.
Apply it
If a candidate changes phone numbers and plans to travel, update contact details through approved procedures, review how to report changes, and document the conversation. Verify the candidate knows how the program will reach them about time-sensitive matters.
Common pitfall: Do not assume old contact information remains reliable or communicate a status change without practical next steps. Verify required notifications. Do not leave a candidate uncertain about whom to call or what information to report.
OPTN Policies — effective October 1, 2026 · ABTC Candidate Handbook — currently linked August 13, 2026 file
Post-operative Monitoring, Evaluation, and Reporting39%
38.How should a persistent, unexplained rise in kidney allograft creatinine be approached?
A persistent, unexplained increase requires assessment rather than assumption. Possible causes include rejection and nonimmune problems. The KDIGO 2009 Kidney Transplant Recipient Guideline identifies allograft biopsy as an important investigation for persistent unexplained elevation; this is a specific, stable principle from that guideline, not newly issued guidance. The team determines whether biopsy is indicated.
Apply it
If repeat testing confirms creatinine remains above baseline without an established explanation, alert the transplant team and facilitate its assessment plan. Confirm who will review the result, what additional information is needed, and when follow-up will occur.
Common pitfall: Do not label one result as rejection or dismiss a persistent trend. Follow the responsible team's diagnostic plan and document who will act. Do not direct biopsy or treatment independently, and do not imply the 2009 guideline is newly issued.
KDIGO: Transplant Recipient · KDIGO 2009 Kidney Transplant Recipient Guideline: Summary · NIDDK: Kidney Transplant
39.Why does tacrolimus monitoring depend on collection timing?
Tacrolimus concentrations are interpreted with dose timing, formulation, interactions, and patient condition. The KDIGO 2009 Kidney Transplant Recipient Guideline includes trough monitoring as a specific, stable principle, not newly issued guidance. A trough is meaningful only when collected at the intended time relative to dosing. Verify timing and communicate discrepancies; the team uses results for medication decisions.
Apply it
If a level was drawn shortly after a dose instead of at the instructed interval, clarify timing with the laboratory and team before treating it as a valid trough. Record actual collection time and coordinate whether repeat testing is wanted.
Common pitfall: A number without collection timing can mislead. Avoid casual comparisons across formulations or unsupervised dose changes, and communicate relevant recent medication changes. Do not describe a mistimed level as a confirmed trough.
KDIGO: Transplant Recipient · KDIGO 2009 Kidney Transplant Recipient Guideline: Summary · DailyMed: Tacrolimus Capsules Prescribing Information
40.How can a newly prescribed interacting medication affect tacrolimus safety?
Some medicines alter tacrolimus exposure. Prescribing information identifies fluconazole among medicines that can increase tacrolimus concentrations. Check the complete medication list, communicate new or stopped medicines to the transplant team, and follow its monitoring and medication instructions. An interaction calls for coordination, not independent discontinuation or a generic dose change.
Apply it
If a community clinician prescribes fluconazole to a recipient taking tacrolimus, alert the transplant team and confirm its plan for monitoring and medication management. Verify the recipient knows which clinician to contact with questions.
Common pitfall: Do not advise stopping an essential medicine independently or assume an interaction is harmless because both drugs were prescribed. Verify details and close the communication loop. Avoid issuing a dose adjustment without authorization or relying on an incomplete medication list.
41.How should symptoms and laboratory findings be used when infection or rejection is possible?
Infection and rejection can produce overlapping or nonspecific findings. Neither a symptom pattern nor a single laboratory result necessarily establishes a diagnosis. Assess urgency, gather timing and medication context, and involve the transplant team for evaluation. The team determines testing and treatment from the full clinical picture. Communicate observations separately from suspected explanations and assign the next action.
Apply it
If a recipient develops fatigue and a new laboratory abnormality without a clear cause, report findings and context and arrange team-directed assessment. Include the trend, baseline, timing, associated symptoms, and recent medication changes.
Common pitfall: Do not start leftover antimicrobials or change immunosuppression based on a guess. Do not reassure solely because a classic symptom is absent; document the team's plan. Avoid presenting a possibility as a confirmed diagnosis or allowing an abnormal result to go unreviewed.
ABTC Candidate Handbook — currently linked August 13, 2026 file
42.Which symptoms may require emergency rather than routine transplant follow-up?
Triage urgency according to severity and follow local emergency procedures. Chest pressure with shortness of breath or sweating is a potential emergency; American Heart Association guidance supports emergency response. Notify the transplant team as appropriate, but do not delay urgent evaluation while trying to establish a transplant-specific diagnosis.
Apply it
If a recipient reports chest pressure, breathlessness, and sweating, direct immediate emergency evaluation under local protocol and notify the transplant team without delaying care. Use the emergency pathway for severe or rapidly worsening symptoms.
Common pitfall: Do not route potentially life-threatening symptoms only to a routine clinic callback or assume their cause without assessment. Emergency care takes priority over nonurgent coordination. Do not delay emergency services while gathering a complete history or seeking team permission.
American Heart Association: Warning Signs of a Heart Attack · ABTC Candidate Handbook — currently linked August 13, 2026 file
43.What does donor-positive, recipient-negative CMV status mean for a kidney transplant?
PREVYMIS prescribing information identifies a CMV-seropositive donor paired with a CMV-seronegative kidney recipient as a high-risk transplant category. This informs the team's prevention and monitoring assessment but does not prove active infection or prescribe a regimen by itself. Verify that the pairing is documented and routed to the team responsible for individualized care planning.
Apply it
If the donor is CMV positive and the kidney candidate is CMV negative, confirm the pairing is recorded and considered by the responsible team before transplant planning proceeds. Route prevention and monitoring questions to the team using the current care plan.
Common pitfall: Do not infer active infection from serostatus alone or select medication or duration without clinical direction. Serostatus is a risk factor to incorporate into planning, not a diagnosis. Do not substitute a risk category for the recipient's individualized monitoring plan.
44.How should sustained decline in lung function be evaluated?
The reference baseline is the mean of the two best postoperative FEV1 measurements taken more than three weeks apart. A decline of at least 20% from that baseline is a threshold prompting evaluation for CLAD, not a diagnosis by itself. Confirmation requires persistent decline for three months after the initial qualifying value and assessment and treatment of secondary causes. The team evaluates potentially reversible causes.
Apply it
If repeated spirometry shows a decline of at least 20% from the reference baseline, report measurements and dates promptly and coordinate evaluation of secondary causes with the team. Track assessment and treatment and whether the decline persists over the required period.
Common pitfall: Do not diagnose CLAD from a single low result or threshold alone. Confirm the reference baseline and persistence, and ensure secondary causes are assessed and treated. Do not delay communication while waiting to assign a definitive syndrome label.
ISHLT 2019 Consensus Report: Chronic Lung Allograft Dysfunction
45.What should happen when liver tests become abnormal after transplantation?
Abnormal liver tests can reflect graft, biliary, vascular, infectious, medication-related, or systemic problems. Pattern and context guide evaluation; a laboratory result alone does not establish a cause. Compare with prior results, review symptoms and medication changes, and relay findings for team-directed investigation. The coordinator facilitates timely testing and consultation while leaving diagnosis and treatment to the clinical team.
Apply it
If a liver recipient develops a new abnormal pattern after a medication change, communicate the trend and medication history and coordinate team-directed assessment. Confirm who will review the information and whether repeat testing or consultation is planned.
Common pitfall: Do not label every abnormal result as rejection, wait for symptoms before escalating a meaningful trend, or change medication without direction. Share actual data and context. Do not attribute a result to medication without review.
EASL 2024 Clinical Practice Guidelines on Liver Transplantation
46.Which long-term complications deserve continuing attention?
Long-term care includes assessment for medication-associated and disease-related complications such as hypertension, diabetes, osteoporosis, infection, malignancy, and graft loss. Risks require continuing coordination, not a one-time discharge discussion. The regimen, laboratory trends, history, and organ type guide the plan. Track surveillance and health-maintenance tasks with the responsible team, alongside appropriate primary care.
Apply it
If a recipient develops rising blood pressure and glucose during follow-up, communicate the trends to the team rather than assuming a single cause and coordinate assessment. Check whether the recipient knows which service will address each concern.
Common pitfall: Do not attribute every new condition to one medicine without assessment. Graft visits do not replace broader health maintenance, preventive care, or primary-care follow-up. Avoid assuming a complication is resolved because the recipient has no symptoms or one result improved.
EASL 2024 Clinical Practice Guidelines on Liver Transplantation · DailyMed: Tacrolimus Capsules Prescribing Information · ABTC Candidate Handbook — currently linked August 13, 2026 file
47.Why is skin-cancer prevention part of long-term transplant care?
Immunosuppression is associated with increased malignancy risk, and tacrolimus prescribing information includes skin-cancer precautions. Support prevention education and surveillance in coordination with the transplant team and primary care. Encourage assessment of concerning skin changes through the recommended pathway. Prevention and timely evaluation are part of continuing health maintenance, not substitutes for assessing a specific lesion.
Apply it
If a recipient notices a changing skin lesion and has not arranged follow-up, encourage clinical assessment and reinforce the center's prevention and surveillance advice. Help identify the appropriate clinician and document agreed follow-up.
Common pitfall: Do not dismiss a lesion because it is small or painless, and do not claim it is malignant without assessment. Help the recipient reach the appropriate clinician. Avoid substituting general advice for the recipient's surveillance plan or assuring them a lesion is harmless.
DailyMed: Tacrolimus Capsules Prescribing Information · ABTC Candidate Handbook — currently linked August 13, 2026 file
48.How can medication affordability be addressed before discharge?
A discharge regimen is not workable if the recipient cannot obtain it. Identify cost, coverage, prior authorization, billing, or pharmacy access problems and coordinate financial services, pharmacy, and the clinical team. Confirm where and how medications will be obtained. Resolve uncertainties early enough for the responsible team to assess a safe plan before discharge.
Apply it
If a recipient says the discharge pharmacy quote is unaffordable, contact financial and pharmacy supports promptly and alert the team to risk of treatment interruption. Confirm whether coverage or an authorized access pathway has actually been arranged.
Common pitfall: Do not suggest rationing or substitute a drug without authorization. Treat access as a safety issue requiring coordinated resolution before assuming discharge medications are secured. A referral alone does not establish access.
AHRQ: Help Patients Pay Less for Medicine, Tool 19 · ABTC Candidate Handbook — currently linked August 13, 2026 file
49.What does safe discharge medication coordination require?
Confirm that the medication plan is reconciled, understandable, and accessible. Clarify what changed, who will prescribe or monitor each medicine, how refills will be obtained, and which interactions or effects require contact. Use teach-back and confirm actual access rather than relying on a printed list alone. Escalate unresolved discrepancies to the transplant team.
Apply it
If the discharge list conflicts with the preadmission list, reconcile it with the prescriber or pharmacist and explain the confirmed plan using teach-back. Ask how the recipient will obtain each medicine and what to do if supply is delayed.
Common pitfall: Do not assume every medicine on a list should continue or ask the recipient to resolve conflicting prescriptions independently. Confirm ownership for follow-up and refills. A written list does not prove the regimen is accurate, understood, or obtainable.
ABTC Candidate Handbook — currently linked August 13, 2026 file · AHRQ: Use the Teach-Back Method, Tool 5
50.How can polypharmacy increase post-transplant medication risk?
Multiple concurrent medicines can increase the chance of interactions, duplication, adverse effects, and confusion. Maintain an accurate medication list and ensure new prescriptions, over-the-counter products, and supplements are reviewed by an appropriate clinician or pharmacist. Communicate changes across providers. The aim is to identify and coordinate risk, not to stop useful treatment reflexively.
Apply it
If a recipient reports adding an over-the-counter product after a specialist visit, record it and request transplant pharmacist or team review for interactions. Ask whether other clinicians changed medicines and ensure the updated list reaches the appropriate team.
Common pitfall: Do not assume nonprescription products are interaction-free or advise stopping a prescribed medicine without an authorized decision. Reconcile changes across providers. Do not rely on an old list when assessing a new symptom or medication concern.
DailyMed: Tacrolimus Capsules Prescribing Information · ABTC Candidate Handbook — currently linked August 13, 2026 file
51.How should psychosocial complications after transplantation affect coordination?
Post-transplant barriers can include financial coverage, caregiver support, transportation, utilities, adherence challenges, or trauma. Assess respectfully and coordinate social work, mental-health, financial, or community resources as appropriate. Communicate unresolved safety concerns to the team and check whether proposed support worked. A referral alone does not establish that a barrier has been resolved.
Apply it
If a recipient misses laboratory visits because caregiver support ended and transportation is unreliable, coordinate with social work and the transplant team on a feasible plan. Confirm which service will contact the recipient and whether testing is practically accessible.
Common pitfall: Do not label missed care as noncompliance without exploring causes or treat a referral as proof of resolution. Confirm whether the person can access proposed support. Avoid blaming language and communicate important follow-up gaps.
ABTC Candidate Handbook — currently linked August 13, 2026 file · AHRQ: Help Patients Pay Less for Medicine, Tool 19
52.How must post-transplant OPTN/UNET data be reported?
The CCTC outline includes required post-transplant OPTN/UNET reporting, including specified clinical values and events such as graft failure, malignancy, and transfer of care. Use current policy and approved system processes. Validate entries against the clinical record and responsible team, resolve missing or conflicting information, and retain appropriate documentation. Confirm the report is complete and submitted within the applicable timeframe.
Apply it
If a report requests a graft-failure event but the record is unreconciled, confirm the event and details with the clinical record and responsible team before submission. Document the source and clarify who will complete the report if responsibilities are shared.
Common pitfall: Do not omit required data for convenience or enter estimates as facts. Check current reporting requirements rather than relying on an outdated checklist or assumption. Do not assume another facility or coordinator submitted the report without confirmation.
OPTN Policies — effective October 1, 2026 · ABTC Candidate Handbook — currently linked August 13, 2026 file
53.How do organ-specific functions affect post-transplant monitoring?
Monitoring should reflect the function of each transplanted organ, not just general immunologic or medication risks. Kidney surveillance includes laboratory assessment of kidney function, and problems can be asymptomatic. Pancreas graft concerns may involve endocrine function, including blood-glucose regulation; intestine graft concerns may involve intestinal function, including nutrient and fluid absorption. A combined-organ recipient may therefore have distinct concerns across grafts even when one set of findings is stable.
Apply it
If a kidney-pancreas recipient reports new difficulty with glucose control while kidney tests appear stable, promptly communicate the change and coordinate pancreas-focused assessment with the transplant team. For an intestinal recipient, report a meaningful change in intestinal function and coordinate review under the recipient's specific plan. Ensure information about each graft reaches the appropriate clinicians.
Common pitfall: Normal kidney tests do not establish normal pancreas or intestine function, and symptoms or findings related to one graft do not determine the status of another. Do not apply a single-organ monitoring plan to a multi-organ recipient or infer a diagnosis from one finding. Follow the transplant-specific plan and team assessment.
HRSA OPTN: Pancreas · HRSA OPTN: Intestine · NIDDK: Kidney Transplant · ABTC Candidate Handbook — currently linked August 13, 2026 file
54.When does post-transplant care require coordination across specialties?
A complication may require services beyond the transplant clinic, including infectious disease, interventional radiology, gastroenterology, endocrinology, cardiology, dialysis, or emergency services. Share relevant transplant history and plans, clarify who owns the next action, and ensure results return to the transplant team. The coordinator facilitates communication without replacing each service's clinical responsibilities.
Apply it
If a recipient needs an outside procedure while immunosuppression is being adjusted, confirm teams share relevant history and identify who will communicate the results. Record the agreed follow-up contact and check that the transplant team receives the outcome.
Common pitfall: Do not assume outside providers have the complete transplant history or that another team has accepted responsibility for follow-up. Identify a contact and close the loop. Avoid unauthorized disclosure or leaving a result without an assigned reviewer.
ABTC Candidate Handbook — currently linked August 13, 2026 file
55.What makes an escalation useful when the diagnosis is uncertain?
Report the finding, trend, timing, symptoms, relevant baseline, and context such as medication changes or pending tests. Separate observation from suspected diagnosis. Identify who received the information, what action was agreed, and when follow-up will occur. Closed-loop communication helps the responsible clinician assess urgency and next steps.
Apply it
If a recipient has a new laboratory abnormality without symptoms, report the value, trend, baseline, and medication context; confirm who will review it and when. Document instructions, planned repeat testing, or escalation criteria communicated to the recipient.
Common pitfall: Do not report only that labs are abnormal or describe a suspected diagnosis as confirmed. Confirm the handoff and plan, then document disposition. Leaving a message or placing a referral does not mean the concern has been reviewed.
ABTC Candidate Handbook — currently linked August 13, 2026 file
56.Why does kidney-graft surveillance rely on serial laboratory trends even in asymptomatic recipients?
A transplanted kidney can have functional problems without symptoms, so how the recipient feels cannot establish graft function. Scheduled laboratory assessment, including kidney-function tests, helps the team detect and interpret changes against the recipient's prior results and clinical context. Serial kidney results are distinct from general home monitoring: temperature, blood pressure, and weight may be useful observations, but they do not measure kidney-graft function or replace ordered laboratory surveillance.
Apply it
If an asymptomatic kidney recipient misses blood tests, explain that the tests assess graft function even when the recipient feels well. Help arrange the next test, clarify who will review it, and address barriers to completing the scheduled surveillance.
Common pitfall: Do not equate reassuring symptoms or home measurements with stable kidney function, or treat one isolated result as a diagnosis. Do not substitute a general home-monitoring plan for the recipient's laboratory schedule or independently change that schedule.
57.What should trigger prompt assessment after heart transplantation?
New or worsening dyspnea, reduced exercise tolerance, edema, or palpitations in a heart-transplant recipient warrants prompt communication with the transplant team. These findings are nonspecific and do not establish rejection or graft dysfunction; the team determines assessment. Distinguish prompt transplant-team review from emergency care: severe or rapidly worsening symptoms, or chest pressure with breathlessness or sweating, call for emergency evaluation rather than a routine clinic callback.
Apply it
If a heart-transplant recipient reports new breathlessness and a clear decline in usual activity tolerance, promptly contact the transplant team and relay the change from baseline and any associated symptoms. If symptoms are severe, rapidly worsening, or include emergency warning signs, direct immediate emergency evaluation without waiting for a clinic response.
Common pitfall: Do not diagnose rejection from symptoms, reassure because the recipient has no fever, or delay emergency care while seeking routine follow-up. Lack of one expected symptom does not rule out a serious complication. Report meaningful changes even when their cause is uncertain.
ABTC Candidate Handbook — currently linked August 13, 2026 file · American Heart Association: Warning Signs of a Heart Attack
58.How should infection evaluation be coordinated after transplantation?
Immunosuppressed recipients may face bacterial, viral, and fungal infections, and symptoms can vary. Coordinate evaluation using symptoms, examination, laboratory studies, and relevant history. Communicate concerns promptly and track ordered testing to completion. Testing and treatment decisions belong to the transplant team and appropriate clinicians, who interpret the full clinical picture.
Apply it
If a recipient reports a productive cough and feels worse than usual, follow the center's triage instructions, communicate symptoms and timing, and track team-directed evaluation. Confirm what the recipient should do if symptoms worsen while awaiting assessment.
Common pitfall: A mild presentation does not exclude significant infection. Do not recommend leftover antimicrobials or change immunosuppression without direction; document the assessment pathway. Do not delay communication because a symptom is nonspecific or fever is absent.
ABTC Candidate Handbook — currently linked August 13, 2026 file · CDC: Safer Food Choices for People With Weakened Immune Systems
59.What complications and monitoring clues should the team consider during rejection treatment?
Rejection treatment can create risks distinct from rejection itself. High-dose corticosteroids can cause substantial hyperglycemia and increase infection risk; follow ordered glucose monitoring and promptly report marked elevations or symptoms of infection. Lymphocyte-depleting therapy can cause infusion reactions and cytopenias, so ordered blood counts and symptoms such as fever, chills, unusual bruising, or bleeding matter. Intensified tacrolimus exposure can contribute to nephrotoxicity and neurotoxicity; the transplant team may follow trough concentrations, kidney function, and neurologic symptoms. These clues support timely assessment, not independent diagnosis or medication changes.
Apply it
When a recipient reports fever or chills during rejection treatment, new bruising, markedly elevated glucose, reduced urine output, or new tremor or confusion, document the symptom, timing, and current treatment context and promptly contact the responsible transplant team. Confirm which ordered monitoring remains outstanding—such as glucose checks, blood counts, kidney-function tests, or tacrolimus troughs—and who will review results. Escalate severe or rapidly worsening symptoms through the program’s urgent-response pathway.
Common pitfall: Do not dismiss fever as an expected treatment effect, since infection may be important during intensified immunosuppression. A low blood count, high glucose, creatinine change, or neurologic symptom also requires interpretation in clinical context; it does not by itself establish a complication. Do not hold or adjust rejection therapy or immunosuppression independently. Ensure each result or symptom has a named clinician responsible for review and follow-up.
ABTC Candidate Handbook — currently linked August 13, 2026 file · KDIGO 2009 Kidney Transplant Recipient Guideline: Summary · DailyMed: Tacrolimus Capsules Prescribing Information
60.How can transfer of care preserve transplant-specific safety information?
Communicate transplant history, current medications, recent findings, pending tests, and responsible contacts through authorized channels. Clarify who manages follow-up and how results will reach the transplant team. Document what was sent, to whom, and outstanding actions under applicable reporting and privacy requirements. State urgent issues and whom to contact for clarification.
Apply it
If a recipient moves to a local hospital for evaluation, send approved information, confirm the receiving contact, and identify who should receive updates. Follow up on outstanding results or recommendations so the transplant team remains informed.
Common pitfall: Do not assume records transfer automatically or that outside providers know the regimen. Use authorized processes for confidential information and clarify responsibility for follow-up. Do not leave pending tests without assigning responsibility for review and communication.
OPTN Policies — effective October 1, 2026 · ABTC Candidate Handbook — currently linked August 13, 2026 file
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the current three-domain outline and published weights: Transplant Education 31%, Pre-Transplant Evaluation and Management 30%, and Post-operative Monitoring, Evaluation, and Reporting 39%. The official outline defines the full examination scope; this guide is selective.
- The 20 questions contain 4 Transplant Education, 8 Pre-Transplant Evaluation and Management, and 8 Post-operative Monitoring, Evaluation, and Reporting items. These sets are learning materials, not weighted mock examinations.
- Practise coordinator actions: explain, assess, communicate, coordinate, document, and escalate. Identify which decisions belong to authorized clinicians, candidates, donors, or policy processes.
- Review indications and contraindications, donor autonomy and postoperative follow-up, waitlist status and exception processes, offer review, consent, and preoperative logistics.
- Practise organ-specific distinctions: kidney laboratory surveillance can reveal problems without symptoms; pancreas graft concerns include endocrine function and glucose regulation; intestinal graft concerns include intestinal function; heart recipients' new dyspnea, reduced exercise tolerance, edema, or palpitations warrant prompt team communication. For multi-organ recipients, review each graft rather than assuming one stable result represents all.
- Include basic pediatric principles in study: age-appropriate communication, the appropriate pediatric team's review, organ-size considerations, and applicable consent processes. Do not assume an adult pathway transfers unchanged.
- For U.S. OPTN/UNET topics, verify current policy. Practise identifying uncertainty, urgent symptoms, compatibility questions, medication risks, reporting duties, and access barriers.
A practical preparation plan
1. Start with the current outline
Use the ABTC CCTC outline effective July 1, 2026. Record all three domains and their published weights; do not treat the historical two-domain outline as current. The official outline is the full examination scope.
2. Map tasks to coordinator actions
For each case, identify what must be explained, verified, coordinated, documented, or escalated, and who has authority to make the clinical or policy decision.
3. Study indications, donor care, and consent
Review how suitability is assessed, how donors are protected and followed, what consent and offer decisions require, and which facts need authorized team review.
4. Practise waitlist and allocation processes
Review accurate listing data, status changes, notifications, exception processes, offer information, and preoperative compatibility and logistics. Check current OPTN policy for U.S. tasks.
5. Study across organs and ages
Review kidney, liver, heart, lung, pancreas, intestine, and multi-organ examples, with basic adult and pediatric principles. Compare the organ-specific function or warning finding with the coordinator action it warrants, and use the recipient's actual transplant-specific plan.
6. Practise post-transplant escalation and reporting
For abnormal findings, emergencies, medication questions, and required OPTN/UNET data, practise concise communication, validation, closed-loop follow-up, and role boundaries.
7. Review errors and uncertainty
Answer questions before reading explanations. State the decisive clue, why the best action fits, what uncertainty remains, and what new information could change the decision.
8. Confirm examination logistics
The current handbook describes 175 items, including 150 scored and 25 unscored pretest items, and three hours of testing time. Confirm application, eligibility, scheduling, and administration details directly with ABTC and PSI.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABTC Candidate Handbook
- ABTC Certification Examinations
- ABTC Candidate Handbook — currently linked August 13, 2026 file
- ABTC Candidate Handbook — March 12, 2026 file
- AHRQ: Use the Teach-Back Method, Tool 5
- HRSA OPTN: Living Donation FAQs
- CDC: Safer Food Choices for People With Weakened Immune Systems
- CDC: Altered Immunocompetence
- NIDDK: Kidney Transplant
- KDIGO 2020 Clinical Practice Guideline on Kidney Transplant Candidate Evaluation
- KDIGO: Transplant Recipient
- KDIGO 2009 Kidney Transplant Recipient Guideline: Summary
- HRSA OPTN: CPRA Calculator
- OPTN 2025 Histocompatibility Laboratory Guidance Document
- OPTN Policies — effective October 1, 2026
- HRSA OPTN: Questions and Answers About Liver Allocation
- HRSA OPTN: MELD Calculator
- DailyMed: Tacrolimus Capsules Prescribing Information
- DailyMed: PREVYMIS Prescribing Information
- American Heart Association: Warning Signs of a Heart Attack
- AHRQ: Help Patients Pay Less for Medicine, Tool 19
- ISHLT 2019 Consensus Report: Chronic Lung Allograft Dysfunction
- EASL 2024 Clinical Practice Guidelines on Liver Transplantation
- HRSA OPTN: Pancreas
- HRSA OPTN: Intestine
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.